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2017 WFNOS Meeting Summary  
 
The 5th quadrennial World Federation of Neuro-Oncology Societies (WFNOS) Meeting 
occurred in Zurich, Switzerland from May 4-7, 2017.  The meeting featured 917 
participantseople from 51 countries in attendance with the highest representation from 
the United States and Germany.  Over 430 attendees participated in the preceding 
education day, organized by the European Association of Neuro-Oncology (EANO) and 
the EORTC Brain Tumor Group, with a new World Health Organization (WHO) brain 
tumor classification clinical focus in the morning sessions and a focus on genetic and 
metabolic therapeutic targets in the afternoon.  Abstract submissions included 452 
accepted abstracts, which were published in Neuro-Oncology, Volume 19, Supplement 
3, May 2017.  In addition, the meeting featured 77 oral presentations. Keynote 
addresses were provided by the major charter societies to the WFNOS including 
EANOthe European Association of Neuro-Oncology (“Current concepts and challenges 
of trial design in brain and leptomeningeal metastasis” by Dr. Riccardo Soffietti), ASNO 
(“hTERT in glioma – a multifaceted demigod” by Dr. Koichi Ichimura), and SNO 
(“Immunotherapy: advances and future directions” by Dr. David Reardon).  In closing 
remarks, Dr. Michael Weller of Zurich passed the role of President onto Dr. Yong-Kil 
Hong of Seoul, South Korea.  The WFNOS looks forward and invites all interested 
investigators to the next meeting to take place in 2021 in Seoul, South Korea.  The 
following summarizes a few of the important updates and advances presented at this 
year’s meeting.   
 
 
Checkmate-143: A PD-1 Inhibitor in Recurrent Glioblastoma  
 
Results were presented from cohort 2 of the open-label phase 3 CheckMate-143 study 
evaluating the safety and efficacy of nivolumab compared to bevacizumab in patients 
with recurrent glioblastoma (GBM). In this study, 369 patients with first recurrence of 
GBM were randomized to either nivolumab 3 mg/kg every 2 weeks (n=184) or 
bevacizumab 10 mg/kg every 2 weeks (n=185).  The primary endpoint of overall survival 
(OS) was not met. Median OS was 9.8 months in the nivolumab arm compared to 10.0 
months in the bevacizumab arm (HR = 1.04, p=0.76). Progression-free survival (PFS) 
was1.5 months for nivolumab and 3.5 months for bevacizumab. The objective response 
rate was of 8% with nivolumab and 23% with bevacizumab, although median duration of 
response was 11.1 months for nivolumab and 5.3 months for bevacizumab.  Twelve 
month OS rate was 42% in both arms. Corticosteroids were administered treatment was 
required in 40% of nivolumab and 43% of bevacizumab treated patients.  Serious 
adverse events occurring in greater than 5% of patients included seizure (8% nivolumab 
vs 6% bevacizumab). The authors concluded that this phase 3 study failed to 
demonstrate a survival advantage for nivolumab as monotherapy in patients with 
recurrent glioblastoma as compared to bevacizumab. The safety profile was similar to 
that observed in other tumors. The significance of a somewhat longer median duration 
of radiographic response is unclear.  
 
 
Updated Results from CheckMate-143 in Newly Diagnosed Glioblastoma  
 
Results from the exploratory cohorts 1c and 1d of the CheckMate-143 study were also 
presented. These cohorts evaluated the safety and tolerability of nivolumab in 
combination with radiotherapy with (1c) or without (1d) temozolomide in 110 patients 
with newly diagnosed GBM.  Cohort 1c was composed of 57 patients including those 
with gliomas harboring methylation of the O6-methylguanine-DNA-methyltransferase 
(MGMT) gene promoter (19%), or notunmethylation (68%), or being indeterminate 
(12%).  Cohort 1d consisted of 53 patients including MGMT gene promoter 
unmethylated (96%) or indeterminate (4%) gliomas. Treatment related adverse events 
occurred in 67% of patients in cohort 1c, and 70% of patients in cohort 1d and included 
fatigue (>15%), headache (>13%), and increased ALT (>9%). Grade 3-4 adverse 
advents were rare and reported in >2 patients in either cohort and included elevated 
ALT and increased lipase. No treatment-related deaths were reported. Overall, these 
results suggested that nivolumab when combined with radiation with or without 
temozolomide was associated with acceptable toxicity profile.   
 
 
MGMT Promoter Methylation Status in High-Risk Low Grade Gliomas Predicts 
Progression-Free but not Overall Survival  
 
Data on the prevalence and prognostic significance of MGMT gene promoter 
methylation in high-risk low-grade glioma patients from the NRG Oncology/RTOG 9802 
trial was presented. This phase 3 study enrolled patients with high-risk low grade 
gliomas randomized to radiation therapy versus radiation followed by procarbazine, 
lomustine, and vincristine (PCV). Of the 251 eligible patients, 56 patients (22%) had 
results of MGMT promoter methylation status available. MGMT methylation was 
detected in 77% (n=43) and more common in oligodendrogliomas than astrocytomas. 
MGMT promoter methylation was significantly correlated with improved progression-free 
(PFS, hazard ratio=2.52, p=0.01) and overall survival (OS, HR=2.66, p=0.01). However, 
statistical significance was maintained only for PFS and not OS in the multivariate 
analysis (HR=3.57, p=0.001). The authors concluded that these data represent the first 
study to validate the prognostic significance of MGMT promoter methylation in a 
prospective randomized phase 3 study of high-risk low grade gliomas. Further analysis 
with results of 1p19q codeletion and IDH mutational status are reported to be ongoing 
and will be helpful in defining the role of MGMT promoter methylation as a predictive 
biomarker independent of other molecular characteristics such as IDH mutation or 
1p19q codeletion in high-risk low grade gliomas. 
 
 
TERT and MGMT Molecular Status Improves the Prognostication of 
Glioblastomas 
 
Despite major changes in the World Health Organization (WHO) molecular classification 
of gliomas, TERT promoter mutation is not integral to glioma classification and its 
prognostic significance continues to be explored and updated. Samples from 151 IDH-
wild type diffuse astrocytomas (WHO Grade 2-3) and 453 IDH-wild type GBMs were 
analyzed and reported by a group from Japan. TERT promoter mutations were 
observed in 54% of grade 2-3 gliomas and 58% of GBMs. The presence of TERT 
promoter mutation was associated with significantly shorter overall survival in the grade 
2-3 gliomas (16.1 months vs. 34.8 months, p<0.0001) which was also observed but to a 
lesser degree in GBM (16.3 months vs 20.8 months, p<0.01). When tumors were 
stratified by a combination of TERT and MGMT status, TERT promoter mutation added 
value beyond MGMT methylation status alone. TERT-mutated and MGMT-
unmethylated gliomas had the poorest outcomes. Median OSoverall survival was 14.6 
months for TERT-mutated/MGMT-unmethylated, 18.8 months for TERT-
wildtype/MGMT-unmethylated, 26.5 months for TERT-wildtype/MGMT-methylated, and 
30.0 months for TERT-mutated/MGMT-methylated cases. Consistent with prior reports 
TERT promoter mutation was a poor prognostic marker in both GBMs and grade 2-3 
diffuse astrocytoma. Furthermore, the combination of TERT and MGMT status improves 
the prognostication with TERT-mutated/MGMT-unmethylated tumors having the worst 
and TERT-mutated/MGMT-methylated tumors having the best prognosis.  
 
 
ATRX and TERT Add Prognostic Value in Adult Infiltrating Gliomas 
 
Similarly a group from the United States presented results of molecular characterization 
of 1206 patients from the University of California at San Francisco Adult Glioma Study, 
the Mayo Clinic, and The Cancer Genome Atlas (TCGA) databases. Tumors were 
divided into 1 of 5 categories including: (1) Oligodendroglioma: IDH-mutant; 1p/19q 
codeleted, (2) Astrocytoma: IDH-mutant, (3) Glioblastoma: IDH-mutant, (4) 
Glioblastoma: IDH-wildtype, and (5) Diffuse Glioma: IDH-wildtype.  Univariate and 
multivariate cox proportional hazards analysis revealed that for Group 1 IDH-mutant, 
1p/19q codeleted oligodendrogliomas TERT promoter mutations were associated with 
significantly worse overall survival (HR: 2.72, 95% CI: 1.05-7.04, p=0.04). In Group 5 
IDH-wild type diffuse glioma TERT-wild type tumors were associated with an improved 
overall survival (HR: 0.48, 95% CI: 0.27-0.87, p=0.02). In Groups 2 and 3 IDH-mutant 
diffuse gliomas and glioblastoma, TERT promoter mutation and ATRX did not add 
significantly to prognosis. In Group 4 IDH-wild type glioblastoma, ATRX alterations were 
associated with improved overall survival (HR: 0.36, 95% CI: 0.17-0.81, p=0.01). This 
study provided substantial data on the role of TERT and ATRX in molecular 
prognostication in glioma. TERT promoter mutation was most helpful in patients with 
Kommentiert [WM1]: Abbreviate throughout or not…. 
1p/19q codeleted oligodendrogliomas and IDH-wild type diffuse gliomas; ATRX was 
most helpful in IDH-wild type glioblastoma. 
 
 
Development of a TERT-Targeting Therapy Using Eribulin Mesylate in a Mouse 
Glioblastoma Model  
 
Given the prevalence of TERT promoter mutation in up to 60-80% of gliomas, TERT is a 
potentially attractive therapeutic candidate for molecular targeting. A group from Japan 
presented preclinical data on a potential novel target of TERT activity. Based on the 
recent observation that TERT has RNA-dependent RNA polymerase activity, this group 
identified the compound eribulin through drug screening analysis as an agent that 
targets this non-canonical activity of TERT. In vitro cytotoxicity assays were performed 
in seven glioma cell lines and established an IC50 below 1nM.  In vivo U87 
subcutaneous flank athymic mice models treated with intraperitoneal eribulin decreased 
tumor growth and RdRP activity in a dose dependent manner. Measurable drug was 
observed in as few as 15 minutes after dosing an intracranial U87 mouse model with IV 
eribulin demonstrated which persisted 24 hours despite the fact that corresponding 
plasma drug levels were cleared. Intraperitoneal administration of eribulin significantly 
prolonged the survival of mice with intracranially transplanted U87 malignant glioma 
xenografts (p<0.001). These data provide initial support for the blood brain barrier 
penetration and on-target activity of eribulin in in vitro and in vivo models of 
glioblastoma and support a clinical trial which is being planned.  
 
 
2-hydroxyglutarate Magnetic Resonance Spectroscopy Provides Utility in IDH-
mutant Gliomas 
 
New data on the utility of identifying IDH-mutant gliomas non-invasively by magnetic 
resonance spectroscopy was reported. Researchers compared the diagnostic accuracy 
of measuring 2-hydroxyglutarate (2HG), the abnormally accumulated metaboliteprotein 
found in IDH-mutant gliomas, by single-voxel spectroscopy (SVS) versus multivoxel 
chemical shift imaging (CSI) in a cohort of 50 glioma and healthy adult participants. 
Mean 2HG concentrations were 0.40 (95% CI: 0.15 – 0.65) in IDH mutant tumors 
compared to 0.05 (-0.02 – 0.12) in non-mutated gliomas by SVS. Similar results were 
seen by CSI with mean concentration of 0.35 (0.24 – 0.45) in IDH mutant tumors 
compared to 0.13 (-0.05 – 0.31) in IDH non-mutated tumors. Sensitivity, specificity, and 
accuracy were high for both SVS and CSI techniques in patients with newly diagnosed 
tumors; however, CSI demonstrated significantly better performance in identifying 
recurrent tumor compared to SVS. 
 
 
Award Winning Abstracts  
 
H. Cho (Seoul, Korea) presented data suggesting that branched-chain amino acid 
transaminase 1 (BCAT1) expression levels may be a biomarker for prognosis in IDH-
wild type glioblastoma. Higher BCAT1 expression levels correlated with higher cerebral 
blood volume on DSC-perfusion imaging and was associated with shorter progression-
free survival (12 vs 43 months, p=0.004).  
 
N. LeMoan (Omniox Inc, San Carlos, CA) presented evidence that OMX, an oxygen 
carrier drug candidate, is capable of delivering oxygen to hypoxic tumor regions, restore 
anti-cancer immune responses, and synergize with immune checkpoint inhibitors to 
improve survival in mouse models of glioblastoma. 
 
J. W. Taylor (San Francisco, CA) discussed results from a phase 2 study evaluating the 
selective CDK4/6 inhibitor, palbociclib, in 22 patients with recurrent GBM. This study 
was stopped early due to futility with 95% of patients progressing within 6 months of 
initiating treatment in this heavily pretreated patient population.   
 
P. Lohmann (Jülich, Germany) presented new data on the role of textural feature 
analysis as a quantitative radiomics tool for differentiating pseudoprogression from 
progression. In this study, textural feature analysis of O-(2-[18F]fluoroethyl)-L-tyrosine 
(FET) PET demonstrated up to 83% accuracy in predicting the IDH genotype in 23 
newly diagnosed glioma patients.  
 
Overall, WFNOS 2017 provided an excellent update on current research trends in 
clinical and experimental Neuro-Oncology from a global perspective, and the Neuro-
Oncology community is looking forward to WFNOS Seoul 2021. Kommentiert [WM2]: Or some other closing remark …… 
